Amylin reportedly stiff-armed $3.5B offer from BMS

Amylin Pharmaceuticals ($AMLN) reportedly shot down a $22-per-share offer from Bristol-Myers Squibb ($BMY), a deal that could have been worth $3.5 billion--and added another pearl to BMS's growing strand. It's unclear why Amylin rejected the Big Pharma proposal, but in any case, BMS hasn't come back for another try. Report

Read more on